Economic and clinical aspects of diabetes regarding self-monitoring of blood glucose

Diabetes Technology and Therapeutics

Volumn 10, Issue SUPPL. 1, 2008, Pages

  Schnell, Oliver ^a   Hummel, Michael ^a   Weber, Christian ^b  

^a INSTITUT FÜR DIABETESFORSCHUNG   (Germany)

^b Institute for Medical Informatics and Biostatistics   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

BLOOD GLUCOSE MONITORING; CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE SYSTEM; HUMAN; INSULIN TREATMENT; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 44249087919     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2008.0017     Document Type: Review

References (62)

1. rd ed. Brussels: International Diabetes Federation, 2006.
2. WHO Study Group on Prevention of Diabetes Mellitus. Technical Report Series No. 844. Geneva: World Health Organization, 1994.
3. Organization for Economic Co-operation and Development (OECD): OECD Health Data 2006. Paris: Organization for Economic Co-operation and Development, 2006.
4. American Diabetes Association: Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20.
5. Johnson JA, Pohar SL, Majumdar SR: Health care use and costs in the decade after identification of type 1 and type 2 diabetes: a population-based study. Diabetes Care 2006;29:2403-2408.
6. Chan BS, Tsang MW, Lee VW, Lee KK: Cost of type 2 diabetes mellitus in Hong Kong Chinese. Int J Clin Pharmacol Ther 2007;45:455-468.
7. Wallemacq C, Van Gaal LF, Scheen AJ: [The cost of type 2 diabetes: summary of the Cost of Diabetes in Europe-Type II study (CODE-2) and analysis of the situation in Belgium]. Rev Med Liege 2005;60:278-284.
8. Detournay B, Raccah D, Cadilhac M, Eschwege E: Epidemiology and costs of diabetes treated with insulin in France. Diabetes Metab 2005;31(Suppl 3):S3-S18.
9. Hauner H: [The costs of diabetes mellitus and its complications in Germany]. Dtsch Med Wochenschr 2006;131(Suppl 8):S240-S242.
10. Wagenpfeil S, Neiss A, Goertz A, Reitberger U, Stammer H, Spannheimer A, Liebl A: Bootstrap confidence intervals for costs-of-illness of type 2 diabetes mellitus in Germany. Value Health 2002;5:398-404.
11. Weber C, Neeser K, Wenzel H, Schneider B: Cost of type 2 diabetes in Germany over 8 years (the ROSSO study No.2). J Med Econ 2006;9:45-53.
12. Lucioni C, Garancini MP, Massi-Benedetti M, Mazzi S, Serra G: The costs of type 2 diabetes mellitus in Italy: a CODE-2 sub-study. Treat Endocrinol 2003;2:121-133.
13. Nolan JJ, O'Halloran D, McKenna TJ, Firth R, Redmond S: The cost of treating type 2 diabetes (CODEIRE). Ir Med J 2006;99:307-310.
14. van Os N, Niessen LW, Koopmanschap MA, van der Lei J: [Detailed analysis of the societal costs of diabetes mellitus]. Ned Tijdschr Geneeskd 2000;144:842-846.
15. Schmitt-Koopmann I, Schwenkglenks M, Spinas GA, Szucs TD: Direct medical costs of type 2 diabetes and its complications in Switzerland. Eur J Public Health 2004;14:3-9.
16. Weber C, Schneider B, Holm M, Neeser K: Cost impact of blood glucose self-monitoring on complications of type 2 diabetes: a Swiss perspective (ROSSO study No.11). Swiss Med Wkly 2007;137:545-550.
17. Massi-Benedetti M: The cost of diabetes type II in Europe: the CODE-2 Study. Diabetologia 2002;45:S1-S4.
18. Minshall ME, Plauschinat CA, Palmer AJ, Roze S: Economic evaluation of oral antidiabetic drugs in the USA: are they cost-effective in preventing diabetes complications [abstract]? Diabetes 2006;55:A554.
19. O'Brien JA, Shomphe LA, Kavanagh PL, Raggio G, Caro JJ: Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:1122-1128.
20. UKPDS Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
21. Stearne MR, Palmer SL, Hammersley MS, Franklin SL, Spivey RS, Levy JC, Tidy CR, Bell NJ, Steemson J, Barrow BA, Coster R, Waring K, Nolan J, Truscott E, Walravens N, Cook L, Lampard H, Merle C, Parker P, McVittie J, Draisey I, Murchison LE, Brunt AHE, Williams MJ, Pearson DW, Petrie XMP, Lean MEJ, Walmsley D, Lyall MJ, Christie E, Church J, Thomson E, Farrow A, Stowers JM, Stowers M, McHardy K, Patterson N, Wright AD, Levi NA, Shearer ACI, Thompson RJW, Taylor G, Rayton S, Bradbury M, Glover A, Smyth-Osbourne A, Parkes C, Graham J, England P, Gyde S, Eagle C, Chakrabarti B, Smith J, Sherwell J, Kohner EM, Dornhurst A, Doddridge MC, Dumskyj M, Walji S, Sharp P, Sleightholm M, Vanterpool G, Rose C, Frost G, Roseblade M, Elliott S, Forrester S, Foster M, Myers K, Chapman R, Hayes JR, Henry RW, Featherston MS, Archbold GPR, Copeland M, Harper R, Richardson I, Martin S, Foster M, Davison HA, Hadden DR, Kennedy L, Atkinson AB, Culbert AM, Hegan C, Tennet H, Webb N, Robinson I, Holmes J, Foster M, Bell PM, McCance DR, Rutherford J, Nesbitt S, Spathis AS, Hyer S, Nanson ME, James LM, Tyrell JM, Davis C, Strugnell P, Booth M, Petrie H, Clark D, Rice B, Hulland S, Barron JL, Yudkin JS, Gould BJ, Singer J, Badenock A, Walji S, Eckert M, Alibhai K, Marriot E, Cox C, Price R, Fernandez M, Ryle A, Clarke S, Wallace G, Mehmed E, MacFarlane S, Greenwood RH, Wilson J, Denholm MJ, Temple RC, Whitfield K, Johnson F, Munroe C, Gorick S, Duckworth E, Flatman M, Rainbow S, Borthwick LJ, Wheatcroft DJ, Seaman RJ, Christie RA, Wheatcroft W, Musk P, White J, Mc-Dougal S, Bond M, Raniga P, Newton RW, Jung RT, Roxburgh C, Kilgallon B, Dick L, Foster M, Waugh N, Kilby S, Ellingford A, Burns J, Fox CV, Holloway MC, Coghill HM, Hein N, Fox A, Cowan W, Richard M, Quested K, Evans SJ, Paisey RB, Brown NPR, Tucker AJ, Paisey R, Garrett F, Hogg J, Park P, Williams K, Harvey P, Wilcocks R, Mason S, Frost J, Warren C, Rocket P, Bower L, Roland JM, Brown DJ, Youens J, Stanton-King K, Mungall H, Ball V, Maddison W, Donnelly D, King S, Griffin P, Smith S, Church S, Dunn G, Wilson A, Palmer K, Brown PM, Humphriss D, Davidson AJM, Rose R, Armistead L, Townsend S, Poon P, Peacock IDA, Culverwell NJC, Charlton MH, Connolly BPS, Peacock J, Barrett J, Wain J, Beeston W, King G, Hill PG, Boulton AJM, Robertson AM, Katoulis V, Olukoga A, McDonald H, Kumar S, Abouaesha F, Abuaisha B, Knowles EA, Higgins S, Booker J, Sunter J, Breislin K, Parker R, Raval P, Curwell J, Davenport H, Shawcross G, Prest A, Grey J, Cole H, Sereviratne C, Young RJ, Dornan TL, Clyne JR, Gibson M, O'Connell I, Wong LM, Wilson SJ, Wright KL, Wallace C, McDowell D, Burden AC, Sellen EM, Gregory R, Roshan M, Vaghela N, Burden M, Sherriff C, Clarke J, Grenfell J, Tooke JE, MacLeod K, Searnark C, Rammell M: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998;317:703-713.
22. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-986.
23. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75: 894-903.
24. UKPDS Group: Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865.
25. Nathan DM, Cleary PA, Backlund JYC, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B: Intensive diabetes treatment and cardiovascular disease in pa-tients with type 1 diabetes. N Engl J Med 2005;353: 2643-2653.
26. Gaede P, Vedel P, Parving HH, Pedersen O: Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-622.
27. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591.
28. Schnell O, Schafer O, Kleybrink S, Doering W, Standl E, Otter W: Intensification of therapeutic approaches reduces mortality in diabetic patients with acute myocardial infarction: the Munich Registry. Diabetes Care 2004;27:455-460.
29. Standl E, Schnell O: A new look at the heart in diabetes mellitus: from ailing to failing. Diabetologia 2000;43:1455-1469.
30. Otter W, Winter M, Doering W, Standl E, Schnell O: CRP in diabetic and non-diabetic patients with acute myocardial infarction. Diabetes Care 2007;36:3080-3082.
31. Raikou M, McGuire A: The economics of screening and treatment in type 2 diabetes mellitus. Pharmacoeconomics 2003;21:543-564.
32. Vijgen SMC, Hoogendoorn M, Baan CA, de Wit GA, Limburg W, Feenstra TL: Cost effectiveness of preventive interventions in type 2 diabetes mellitus - a systematic literature review. Pharmacoeconomics 2006;24:425-441.
33. Brown JB, Nichols GA, Glauber HS, Bakst AW, Schaeffer M, Kelleher CC: Health care costs associated with escalation of drug treatment in type 2 diabetes mellitus. Am J Health Syst Pharm 2001;58:151-157.
34. Ward A, O'Brien JA, Salas M: Cost-effectiveness of oral hypoglycaemic agents for the treatment of type 2 diabetes mellitus. Expert Opin Pharmacother 2005;6:601-608.
35. International Diabetes Federation: Global Guidelines for Type 2 Diabetes. Brussels: IDF, 2005.
36. Hönes J, Müller P, Surridge N: The technology behind glucose meters: test strips. Diabetes Technol Ther 2008;10(Suppl 1):S10-S26.
37. Blonde L, Karter AJ: Current evidence regarding the value of self-monitored blood glucose testing. Am J Med 2005;118(Suppl 9A):20S-26S.
38. Martin S, Schneider B, Heinemann L, Lodwig V, Kurth HJ, Kolb H, Scherbaum W: Self-monitoring of blood glucose in type 2 diabetes and long-term outcome: an epidemiological cohort study. Diabetologia 2006;49:271-278.
39. Karter AJ, Ackerson LM, Darbinian JA, D'Agostino RB Jr, Ferrara A, Liu J, Selby JV: Self-monitoring of blood glucose levels and glycemic control: the Northern California Kaiser Permanente Diabetes registry. Am J Med 2001;111:1-9.
40. Karter AJ, Parker MM, Moffet HH, Spence MM, Chan J, Ettner SL, Selby JV: Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006;29:1757-1763.
41. Franciosi M, Pellegrini F, De Berardis G, Belfiglio M, Di Nardo B, Greenfield S, Kaplan SH, Rossi MC, Sacco M, Tognoni G, Valentini M, Nicolucci A: Self-monitoring of blood glucose in non-insulin-treated diabetic patients: a longitudinal evaluation of its impact on metabolic control. Diabet Med 2005;22:900-906.
42. Davis WA, Bruce DG, Davis TME: Is self-monitoring of blood glucose appropriate for all type 2 diabetic patients? The Fremantle Diabetes Study. Diabetes Care 2006;29:1764-1770.
43. Davis WA, Bruce DG, Davis TM: Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle Diabetes Study. Diabetologia 2007;50:510-555.
44. Schnell O, Heinemann L: Self-monitoring of blood glucose in noninsulin-treated patients with type 2 diabetes: a never ending story? J Diabetes Sci Technol 2007;1:614-616.
45. Welschen LM, Bloemendal E, Nijpels G, Dekker JM, Heine RJ, Stalman WA, Bouter LM: Self-monitoring of blood glucose in patients with type 2 diabetes who are not using insulin: a systematic review. Diabetes Care 2005;28:1510-1517.
46. Sarol JN, Nicodemus NA, Tan KM, Grava MB: Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966-2004). Curr Med Res Opin 2005;21:173-183.
47. Jansen JP: Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin 2006;22: 671-681.
48. McGeoch G, Moore RA: Self-monitoring of blood glucose in type-2 diabetes: what is the evidence? Diabetes Metab Res Rev 2007;23:423-440.
49. McAndrew L, Schneider SH, Burns E, Leventhal H: Does patient blood glucose monitoring improve diabetes control?: a systematic review of the literature. Diabetes Educ 2007;33:991-910.
50. Palmer AJ, Dinneen S, Gavin JR, Gray A, Herman WH, Karter AJ: Cost-utility analysis in a UK setting of self-monitoring of blood glucose in patients with type 2 diabetes. Curr Med Res Opin 2006;22:861-872.
51. Clua Espuny JL, Puig Junoy J, Queralt Tomas ML, Palau GA: [Cost-effectiveness analysis of self-monitoring of blood glucose in type 2 diabetics]. Gac Sanit 2000;14:442-428.
52. Neeser K, Erny-Albrecht K, Weber C: Cost-effectiveness of self-monitoring of blood glucose in type 2 diabetic patients not receiving insulin [comment]. Diabetes Care 2006;29:480.
53. Weber C, Neeser K, Schneider B, Lodwig V: Self-measurement of blood glucose in patients with type 2 diabetes: a health economic assessment. J Diabetes Sci Technol 2007;1:676-684.
54. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG: Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000;20:332-342.
55. Weinstein M, Zeckhauser R: Critical ratios and efficient allocation. J Pub Econ 1973;2:147-157.
56. Birch S, Gafni A: Information created to evade reality (ICER): things we should not look to for answers. Pharmacoeconomics 2006;24:1121-1131.
57. Birch S, Gafni A: The biggest bang for the buck or bigger bucks for the bang: the fallacy of the cost-effectiveness threshold. J Health Serv Res Policy 2006;11:46-51.
58. Trueman P, Drummond M, Hutton J: Developing guidance for budget impact analysis. Pharmacoeconomics 2001;19:609-621.
59. Mauskopf J: Prevalence-based economic evaluation. Value Health 1998;1:251-259.
60. Orlewska E, Mierzejewski P: Proposal of Polish guidelines for conducting financial analysis and their comparison to existing guidance on budget impact in other countries. Value Health 2004;7:1-10.
61. Mauskopf JA, Earnshaw S, Mullins CD: Budget impact analysis: review of the state of the art. Expert Rev Pharmacoeconomics Outcomes Res 2005;5:65-79.
62. Mauskopf JA, Sullivan SD, Annemans L, Caro J, Mullins CD, Nuijten M, Orlewska E, Watkins J, Trueman P: Principles of good practice for budget impact analysis: report of the ISPOR Task Force on Good Research Practices-Budget Impact Analysis. Value Health 2007;10:336-347.